ERAS · Erasca, Inc.

Summary

Erasca, Inc. announced financial results for Q4 and full year 2025, reporting net loss of $29.1 million ($0.10 per share) and $124.5 million ($0.44 per share), respectively, with cash of $341.8 million as of December 31, 2025, and pro forma cash of $434 million expected to fund operations into H2 2028. The company highlighted promising early clinical data for ERAS-0015, expanded licensing rights, and completed a $259 million upsized financing.

Key takeaways

• Event Type: Earnings Release and Business Update (Items: 2.02)